Thermo Fisher Scientific Inc to buy Patheon NV for $7.2bn

By Gareth Macdonald

- Last updated on GMT

iStock/VIKTORIUS-73
iStock/VIKTORIUS-73

Related tags English-language films

Thermo Fisher Scientific Inc has announced its intention to buy Patheon NV in a deal agreed by both firms’ boards.

Thermo confirmed the takeover plan today, just hours after Bloomberg​ reported the firms were in talks.

Thermo said it will finance the purchase price with debt of $5.2bn and $2bn in equity.

The firm cited Patheon's small and large molecule contract manufacturing capacity, network of production plants and 9,000 staff as the driver for the deal. The Netherlands-headquartered contractor will become part of Thermo Fisher's Laboratory Products and Services Segment.  

DSM, which owns 48.7m shares in Patheon, said the deal is expected to close before the end of the year.

Evercore ISI analyst Ross Muken was positive about the deal, explaining that Patheon “has unique leverage to the high growth pharma bio-processing end market, which Thermo already services on the product side​.”

He added that: “Thermo brings unique relationships and market share at major BioPharma and Emerging Pharma which should synergize Patheon’s one stop shop approach​.” 

See how the deal will impact Thermo here​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers